Immunic AG

Immunic Appoints Jason Tardio as Chief Operating Officer and President (news with additional features)

Immunic to Participate in Industry and Scientific Conferences in June

Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update

Immunic to Participate in Investor and Scientific Conferences in May

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in RRMS in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation